In addition, a meta-analysis on 10 randomized controlled trials including 724 patients evaluating Tα1 in combination with cisplatin and vinorelbine or gemcitabine, could show that the addition of Tα1 increased overall response rate, tumor control rate, CD4+ and NK cells (83), again supporting the notion that Tα1, by restoring the immune capabilities, might adjuvate standard chemotherapy for improved anti-tumor effects. This evidence concerns the gene CD4 and neoplasm.